Novel photodynamic therapy against biliary tract carcinoma using mono‐<scp>l</scp>‐aspartyl chlorine e6: basic evaluation for its feasibility and efficacy

Nanashima

J Hepato Biliary Pancreat

et al. 2011

Section: Introductionmentioning

confidence: 99%

Advantages of laserphyrin compared with photofrin in photodynamic therapy for bile duct carcinoma

Nanashima

J Hepato Biliary Pancreat

et al. 2011

“…In contrast, hepatocytes that incorporated a large amount of Laserphyrin and bile components were impaired by Laserphyrin. However, this does not cause complications due to the regenerative ability of hepatocytes unless hemorrhage, abscess or bile congestion occurs (10). Based on the above basic experimental findings (10), liver disorders caused by Laserphyrin accumulating in hepatocytes were expected; however, based on clinical experience of radiofrequency irradiation, it was concluded that this may be avoided by adjusting the laser irradiation dose.…”

Section: Discussionmentioning

confidence: 98%

“…Japanese white rabbits were intraperitoneally anesthetized with pentobarbital sodium (Kyoritsuseiyaku Corp., Tokyo, Japan) and underwent laparotomy 4 h following the intravenous administration of Laserphyrin at 63 mg/kg, as previously described (9,10). An incision was made in the duodenum wall, and a 6 Fr sheath was inserted trans-transpapillary.…”

Section: Evaluation Of Glisson's Capsule Ensheathing the Hepatic Artementioning

confidence: 99%

“…To overcome this, a novel second-generation photosensitive substance, talaporfin sodium, was used in the present study. Talaporfin sodium accumulates very rapidly in tumors compared with conventional photosensitive substances, and is excreted by normal tissues (8)(9)(10). The second difficulty is that the charge-coupled device (CCD) camera-equipped cholangioscope typically used for treatment has a large diameter and cannot be advanced into intrahepatic bile ducts.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Photodynamic therapy for biliary tract organ via a novel ultra‑small composite optical fiberscope

Kasuya

Oka²,

Soya

et al. 2017

Exp Ther Med

Self Cite

Abstract. Photodynamic therapy (PDT) is a method used treat tumors via utilizing photodynamic reactions between photosensitive substances with tumor affinity and lasers. For overall bile duct cancers, PDT has been demonstrated to resolve stenosis and improve prognosis; however, when limited to intrahepatic bile duct cancers, modifications to the laser irradiation are necessary as surrounding hepatocytes incorporate a large amount of photosensitive substances. Furthermore, the intrahepatic bile duct is thin, and a guide sheath and thin fiber are necessary to transport laser irradiation probes to the target region. In the present study, a parallel-type ultra-small composite optical fiberscope (COF) with an outer diameter of 1 mm or smaller was developed to target a thin intrahepatic bile duct. PDT was performed using an animal model and talaporfin sodium (Laserphyrin), which is rapidly excreted by hepatocytes and is suitable for use with a long-wavelength laser due to its high tissue penetrating ability. The results demonstrated that Laserphyrin does not cause necrotic changes in the normal biliary tract mucosa. In addition, COF images of sufficient quality were acquired. The present results suggest that COF may be used for the treatment of deep bile duct lesions.

“…An animal model of tumor bearing mice was established by intrahepatically implanting cells of human cholangiocarcinoma cell line NOZ to 4-week-old male BALB/c nu/nu mice [13]. In brief, the NOZ cells suspended in 100 μL of serum-free DMEM medium were inoculated subcutaneously in the back of the male nude mice.…”

Section: Determination Of Talaporfin In Sera and Tissues Of Tumor Beamentioning

confidence: 99%

Rapid and Simple Analysis of N-Aspartylchlor in E6 (Talaporfin) Using Fluorescence Microtiterplate and Its Application for Determination in Cells, Tissues and Blood

Yokoyama¹,

Ebara²,

Nakamura³

et al. 2012

JCT

Self Cite

N-aspartylchlorin e6 (talaporfin) concentrations in cancer cells, mouse liver tissues, and human plasma specimens were determined with fluorescence microtiter plate analysis. Talaporfin standard curves were obtained in each of the sample specimens of cells, mouse tissues, or human plasma including serial concentration of talaporfin. The correlation co-efficiencies (r2) of talaporfin standard curves were 0.99-1.00, and the CV less than 5%. Talaporfin incorporation into cells of human breast cancer cell line MCF-7 after incubating with 25 μg/mL talaporfin for up to 24 h revealed that the t-max of the drug incorporation was approximately 5 h, and the maximum drug concentration incorporated was 25 μg/107 cells. Talaporfin incorporation into MCF-7 cells was significantly decreased in the presence of 3 μg/mL cyc-losporine (p < 0.05). Balb/c nu/nu mice implanted human cholangiocarcinoma NOZ cells in liver were administered intravenously 5mg/mouse of talaporfin, and the tissues of normal liver and tumor, as well as plasma specimens, were analyzed for talaporfin concentrations. The mean (SD) of talaporfin concentration in plasma after 30 min of administration was 41.6 (2.3) μg/mL, while the level decreased to undetectable concentrations 2 h after administration. In contrast, the talaporfin concentrations in normal and tumor tissues after 30 min of administration were 1.1-7.8 μg/g tissue, and the level slightly increased or was almost maintained for up to 2-4 h after administration. The heparinized blood of the healthy subjects was incubated with 25 μg/mL talaporfin for up to 24 h. The plasma talaporfin concentration did not significantly change during the incubation, and thus talaporfin appears not to be incorporated into the blood cells. We established rapid and simple analysis procedures of talaporfin in biological specimens using a fluorescence microtiter plate assay. Using this assay procedure, the unique pattern of talaporfin disposition and pharmacokinetics were revealed in human cancer cells, liver tissues of tumor bearing mice, and human blood